VivoSeq
Other

Resectable

0

Pipeline Programs↗

6

Active Trials↗

1

Companies Involved↗

Resectable is an early-stage landscape with 0 programs across 1 company. The most active players are TCM Biotech International Corp..

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

TCM Biotech International Corp.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

12

clinical trials

Recruiting5 · 42%
Unknown status4 · 33%
Completed2 · 17%
Not yet recruiting1 · 8%

Clinical Trials

Trial Activity

12 trials

HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC
Recruiting·—·Phase 2·NCT07364305·50 enrolled
CEB-01 in Paediatrics With Locally Resectable Abdominal Tumours
Recruiting·CCEBIOTEX·Phase 2·NCT06986811·60 enrolled
A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Recruiting·SSichuan University·Phase 2·NCT06951464·40 enrolled
DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07162506·120 enrolled
A Study of PTX-9908 Injection for Non-resectable HCC with TACE
Recruiting·TTCM Biotech International Corp.·Phase 1/2·NCT03812874·50 enrolled
Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM
Not yet recruiting·FFudan University·Phase 3·NCT05948072·250 enrolled
Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia
Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT00985777·26 enrolled
Study Comparing Isolated Pelvic Perfusion With TNF-α 0.3 mg and Melphalan 1.5 mg/kg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer
Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT00949039·101 enrolled
TACE-HAIC vs. HAIC for Potentially Resectable HCC
Unknown status·SSun Yat-sen University·N/A·NCT03591705·240 enrolled
the Effect of Grazoprevir/Elbasvir and TACE vs. TACE Alone in Prolonging Survival of Patients With Non-resectable HCV Associated HCC.
Unknown status·TTel-Aviv Sourasky Medical Center·N/A·NCT03110055·20 enrolled
Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy
Unknown status·RRenJi Hospital·N/A·NCT05132738·20 enrolled
Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression
Unknown status·UUniversity of Warmia and Mazury·Phase 2·NCT04029428·150 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)